Michael Fero - Twist Bioscience Chief Officer
| TWST Stock | USD 42.23 0.57 1.37% |
Executive
Michael Fero is Chief Officer of Twist Bioscience Corp
| Address | 681 Gateway Boulevard, South San Francisco, CA, United States, 94080 |
| Phone | 800 719 0671 |
| Web | https://www.twistbioscience.com |
Twist Bioscience Management Efficiency
The company has return on total asset (ROA) of (0.1639) % which means that it has lost $0.1639 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3836) %, meaning that it created substantial loss on money invested by shareholders. Twist Bioscience's management efficiency ratios could be used to measure how well Twist Bioscience manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.43 in 2024. Return On Capital Employed is likely to drop to -0.43 in 2024. Non Current Liabilities Total is likely to gain to about 86.5 M in 2024, whereas Total Current Liabilities is likely to drop slightly above 49 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Nicole Esq | HCW Biologics | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Alpa Parikh | Lumos Pharma | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| MD MBA | Eliem Therapeutics | 50 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| David Ege | Seres Therapeutics | 49 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Lee Flowers | HCW Biologics | 78 | |
| Lisa MD | Seres Therapeutics | 65 | |
Management Performance
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 |
Twist Bioscience Corp Leadership Team
Elected by the shareholders, the Twist Bioscience's board of directors comprises two types of representatives: Twist Bioscience inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Twist. The board's role is to monitor Twist Bioscience's management team and ensure that shareholders' interests are well served. Twist Bioscience's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Twist Bioscience's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Emily Leproust, President CEO, Director | ||
| William Banyai, GM Development | ||
| Patrick Finn, Vice President of Sales and Marketing | ||
| Dennis JD, Chief VP | ||
| Kevin Yankton, VP Officer | ||
| Chet Gandhi, Chief Officer | ||
| Michael Fero, Chief Officer | ||
| Siyuan Chen, Chief Officer | ||
| Aaron Sato, Chief Officer | ||
| Dennis Cho, General VP | ||
| James Thorburn, Chief Officer | ||
| Erin Smith, Sr Policy | ||
| Adam Laponis, Chief Officer | ||
| Paula Green, Vice President of Human Resources | ||
| Angela Bitting, Chief Affairs | ||
| Robert Werner, VP Officer |
Twist Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Twist Bioscience a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.75) % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 2.32 B | ||||
| Shares Outstanding | 59.36 M | ||||
| Shares Owned By Insiders | 1.94 % | ||||
| Shares Owned By Institutions | 98.06 % | ||||
| Number Of Shares Shorted | 9.02 M | ||||
| Price To Book | 5.30 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Twist Stock Analysis
When running Twist Bioscience's price analysis, check to measure Twist Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Twist Bioscience is operating at the current time. Most of Twist Bioscience's value examination focuses on studying past and present price action to predict the probability of Twist Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Twist Bioscience's price. Additionally, you may evaluate how the addition of Twist Bioscience to your portfolios can decrease your overall portfolio volatility.